Sponsored

Imugene (ASX: IMU) licences allogeneic cell therapy from US-based Precision Biosciences

August 16, 2023 12:00 PM AEST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Imugene is acquiring a license to azer-cel allogeneic CD19 CAR T cell therapy program.
  • Azer-cel has the potential to become the first approved allo CAR T cell therapy for cancer.
  • onCARlytics program and azer-cel complement each other.
  • Imugene to lease a GMP manufacturing facility to complete clinical trials.

Imugene Limited (ASX: IMU) has inked an agreement with Precision Biosciences, Inc., based in North Carolina in the US, for an exclusive licence to the latter’s azer-cel (azercabtagene zapreleucel) allogeneic CD19 CAR T cell therapy program.

Azer-cell reported encouraging results in the ongoing multi-centre Phase 1b clinical trial (patients with non-Hodgkin’s lymphoma (NHL) and acute B-cell lymphoblastic leukaemia (B-ALL)). The results indicated clinically meaningful activity with an acceptable safety profile. Also, it was found that the therapy was especially strong in DLBCL (Diffuse Large B Cell Lymphoma) patients who relapsed after CAR T therapy.

The company also highlighted that azer-cel complements its onCARlytics platform.

IMU believes that there is the potential to begin a registrational study in 2024 in patients with 3rd and 4th line DLBCL. With this development, azer-cel is expected to become the first FDA-approved allogeneic CAR T therapy for blood cancers.

Azer-cel demonstrated significant results across different trials

Currently, the therapy is under a multi-centre Phase 1b clinical trial. As discussed above, in this trial, azer-cel delivered substantial results, especially in DLBCL patients who had relapsed after auto CAR T therapy.

The data set indicated an overall response rate of 83%, a complete response rate of 61%, with 55% durable response more than or equal to six months in this auto CAR T relapse setting.

The update suggested that 60-70% of patients treated with auto CD19 CAR T cell therapy such as Kymriah®, Yescarta® or Breyanzi® will have cancer recurrence or progression.

Azer-cel reported a positive response rate along with an acceptable safety profile in the broader group of patients with relapsed NHL.

Azer-cel also indicated positive results in DLBCL patients who relapsed after CAR T, and the response rate with molecular remissions in this setting was positive. IMU said that considering this dataset, azer-cel can improve outcomes in the growing and large population with unmet needs.

Data source: Company update

In June 2023, a meeting was held with the FDA to get guidance for entering a phase 2 registration study. IMU said that the intended commercial azer-cel product will be evaluated in the clinic and will be used in the potential registrational clinical trial.

Consideration for acquiring right from Precision

As per the licence agreement, Imugene has agreed to pay Precision Biosciences-

Data source: Company update

The company will fund the transaction through existing cash reserves and can partially pay through its equity if it elects to do so. Moreover, IMU will pay US$3 million as an introduction fee to Chimeric Therapeutics Limited in relation to the acquisition.

Advancing Phase 1b clinical trial

Imugene will lease a state-of-the-art 32,800 sq feet GMP manufacturing facility in North Carolina to finalise a phase 1b and phase 2 registrational clinical trial.  

IMU’s shares last traded at AU$0.094 apiece on 15 August 2023 with a market cap of AU$603.76 million.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.